systemic disorder. It is characterized by predominant deposits of IgA in the kidney mesangium [1] . EndBackground. Platelet-activating factor (PAF ) is a phospholipid mediator with potent inflammatory activ-stage renal disease requiring dialysis or renal transplantation develops in many patients with IgAN. The ities. PAF stimulates IgA synthesis by B cells while IgA aggregates enhance PAF production by neutro-pathophysiology of IgAN has not been elucidated.
Subjects and methods Introduction Subjects
Berger's disease is a frequent idiopathic IgA nephropathy (IgAN ) that occurs in the absence of any informed consent and the agreement of the local ethics pended in 60% ethanol and assayed for PAF activity by platelet aggregation assay [11] . Briefly, aspirin-treated committee. Blood PAF levels were investigated in 33 patients (mean age 44 years, 24 men, nine women, mean creatine washed rabbit platelets were stirred in 300 ml of Tyrode buffer containing 0.25% gelatin, 1 mM creatine phosphate and clearance 88 ml/min) without haemodialysis, kidney transplantation or renal insufficiency and 18 healthy controls 10 U/ml creatine phosphokinase (pH 7.4). The aggregating activity of the samples was measured using a calibration (mean age 47 years, seven men, 11 women). Plasma AHA was assessed in 51 IgAN patients (mean age 40 years, 44 curve obtained with 2.5-20 pg of synthetic PAF (Novabiochem, Switzerland ). The lipid compound extracted men, seven women) and 53 healthy controls (mean age 36 years, 23 men, 30 women). Among patients, 17 exhibited from blood was characterized further on the basis of its aggregating activity in the presence of 0.1 mM CV 3988 renal failure (creatine clearance>80 ml/min) at the time they entered this study. Genotyping of the G994 T mutation of ( Takeda Chemical Industries, Japan) and BN 52021 (Tebu, France), two specific PAF receptor antagonists, and its the AHA gene was investigated in 34 patients with AHA <40 nmol/ml/min, i.e. less than half of the mean AHA in retention time during TLC. healthy controls.
Statistical analysis Acetylhydrolase assay
Differences between groups were assessed by Mann-Whitney U-test. A P <0.05 was considered as significant. Plasma samples obtained after blood centrifugation (600 g, 10 min) were stored at −80°C until AHA assay. volume of 450 ml, and 50 ml of diluted plasma (1550 dilution We first investigated the levels of PAF in blood of in HEPES buffer) were incubated for 20 min at 37°C. The patients with idiopathic IgAN. As shown in Figure 1A , reaction was stopped with 100 ml of bovine serum albumin we found a 2.7-fold increase of PAF in the blood of (10%) and 400 ml of trichloracetic acid (20%). Samples were these patients compared with healthy controls centrifuged (1500 g, 15 min) and supernatants counted in a (50.7±6.8 pg/ml vs 18±5 pg/ml, P=0.003, Mannliquid scintillation counter. Results are expressed as nanom-Whitney U-test). The PAF recovered from blood had oles of degraded PAF per ml of plasma (nmol/min/ml ), as biological and physicochemical characteristics identical means of duplicate determinations. The variation between to those of authentic PAF. Firstly, it induced the duplicates was <6%.
aggregation of washed rabbit platelets that were refractory to arachidonic acid and ADP-mediated Genotyping of the G994 T mutation of the AHA gene pathways. Secondly, the platelet-aggregating activity was totally inhibited by 0.02 mM CV 3988 and BN DNA was prepared from isolated leukocytes. The genotype 52021, two PAF receptor antagonists; and thirdly, on of the AHA gene with regard to the G994 T mutation was determined by an allele-specific polymerase chain reaction TLC, the aggregating activity exhibited a retention (PCR) as previously described [3] . Both rounds of PCR time similar to that of synthetic PAF (data not shown).
were performed under the following conditions: first, one
Elevated levels of PAF can result from lower PAF cycle at 94°C for 5 min; secondly, five cycles at 94°C (60 s), catabolism and, thus, we assessed plasma PAF AHA 56°C (60 s) and 72°C (60 s); thirdly 25 cycles at 94°C (60 s), levels in patients with idiopathic IgAN. As shown in 52°C (60 s) and 72°C (60 s); and fourthly one cycle at 72°C Figure 1B , plasma AHA levels were markedly (P= (5 min) . The sense and antisense primers for the entire exon 9 0.0001, Mann-Whitney U-test) reduced in patients were 5∞-CTATAAATTTATATCATGCTT-3∞
and with idiopathic IgAN (61±2 nmol/ml/min, n=51)
5∞-TTTACTATTCTCTTGCTTTAC-3∞, respectively. The compared with healthy controls (78±4 nmol/ml/min, sense and antisense primers for the partial exon 9 conn=53). No difference could be documented (P=0.13, taining the normal sequence were 5∞-CTATAAATTT-ATATCATGCTT-3∞ and 5∞-TCACTAAGAGTCTGA-Mann-Whitney U-test) between patients with ATAAC-3∞, respectively. The sense and antisense primers (66±5 nmol/ml/min, n=17) and without for the partial exon 9 containing the mutation were (58±2 nmol/ml/min, n=34) renal failure. By using an 5∞-CTATAAATTTATATCATGCTT-3∞ and 5∞-TCACTA-allele-specific PCR, we then investigated the putative AGAGTCTGAATAAA-3∞, respectively. The sizes of the presence of the G994 T transversion in exon 9 of products formed were 160 bp for the entire exon 9 and AHA that is responsible for the loss of its enzymatic 108 bp for the partial exon 9 containing the normal sequence activity. As reported in Figure 2 , patients with IgAN or the mutation. exhibiting a plasma AHA reduced by 50% (i.e. 40 nmol/ml/min) were homozygous for the normal Platelet-activating factor assay allele. Only one representative sample is shown but all 34 IgAN patients had the same pattern (data not A 2 ml aliquot of fresh blood samples was mixed immediately shown). corresponding to the PAF standard were extracted, sus-levels in patients with several kidney diseases [6, 7] . PAF is known to stimulate the release of various cytokines [such as interleukin (IL)-1, IL-6 and tumour necrosis factor a] involved in IgAN [2] . Elevated levels of PAF can result from lower PAF catabolism [2] . We have focused our attention on this hypothesis particularly since plasma PAF AHA level is affected in a wide range of pathologies with a component of inflammation [18] . We observed reduced plasma PAF AHA levels in patients with idiopathic IgAN compared with healthy controls suggesting that the decreased plasma AHA levels in patients with IgAN may partially explain the elevated circulating blood PAF levels. It is of interest that the plasma AHA levels are similar in patients with and without renal failure, indicating that the fall of the plasma Blood PAF concentrations (A) and plasma AHA levels (B) are AHA does not result merely from kidney failure. reported as mean±SEM. (n) denotes the number of samples. *P= However, despite the fact that elevated blood PAF 0.003, **P=0.0001 compared with controls (Mann-Whitney U-test). levels fit well with the decreased AHA levels, we cannot exclude that these elevated levels of PAF might be linked to an elevated PAF production through IgA Fc However, the presence of associated ailments such as diabetes mellitus or systemic lupus erythematosus alpha receptors ( FcaR) from neutrophils rather than to a reduced PAF catabolism. Indeed, neutrophils are might be the origin of these elevated levels of PAF [12, 13] . PAF is implicated during experimental kidney a major source of PAF [19] , IgA induces PAF release from neutrophils [9] , and occupation of FcaR is transplant rejection [14] and blood PAF levels are affected by haemodialysis [15, 16 ] . We have thus increased on neutrophils from patients with IgAN [20] .
Clearly this hypothesis deserves further investigation. investigated blood PAF levels in patients with idiopathic IgAN without haemodialysis, kidney trans-A reduced plasma AHA has been associated with a G994 T mutation in exon 9 of the AHA gene in the plantation or renal insufficiency. The results of the present study reveal increased PAF levels in the blood Japanese population [3, 4, 11, 18 ]. This mutation is reported to influence the degree of proteinuria and the in these patients compared with healthy controls with levels similar to those of controls in previous reports extent of mesangial proliferation in Japanese childhood IgAN [21] . While this mutation is not detected in a [12, 17] . This is the first demonstration of increased levels of PAF in the blood of patients with IgAN in healthy Caucasian population, no result is available concerning patients with IgAN. The results of the the absence of associated diseases. The physiological meaning of these elevated circulating levels of PAF present study indicate that this deficiency, assessed by an allele-specific PCR, is not found in Caucasian requires further evaluation. It is of interest to note that 
